Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free MNOV Stock Alerts

MediciNova (MNOV) Financials

MediciNova logo
$1.42 +0.02 (+1.43%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.42 +0.01 (+0.35%)
As of 07/16/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for MediciNova

Annual Income Statements for MediciNova

This table shows MediciNova's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -9.20 -8.85 -11 -11 -15 -13 -14 -10 -14 -8.57 -11
Consolidated Net Income / (Loss)		 -9.20 -8.85 -11 -11 -15 -13 -14 -10 -14 -8.57 -11
Net Income / (Loss) Continuing Operations		 -9.20 -8.85 -11 -11 -15 -13 -14 -10 -14 -8.57 -11
Total Pre-Tax Income 		-9.20 -8.84 -11 -13 -15 -13 -14 -10 -14 -8.57 -11
Total Operating Income		 -9.22 -8.82 -11 -13 -16 -14 -14 -10 -15 -9.90 -13
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.04 0.00 1.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.04 0.00 1.00 0.00
Operating Revenue		 - - - - - - 0.00 4.04 0.00 1.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.22 8.82 11 13 16 14 14 14 15 11 13
Selling, General & Admin Expense		 5.96 5.81 7.36 8.80 9.96 7.95 6.69 5.72 5.48 5.24 5.48
Research & Development Expense		 3.26 3.02 3.52 4.22 5.63 6.08 7.48 8.54 9.14 5.66 7.19
Total Other Income / (Expense), net		 0.02 -0.02 0.02 0.12 0.92 1.10 0.32 0.08 0.56 1.33 1.63
Interest & Investment Income		 - - 0.07 0.15 0.94 1.15 0.36 0.14 0.81 1.83 1.67
Other Income / (Expense), net		 0.02 -0.01 -0.05 -0.03 -0.02 -0.05 -0.04 -0.06 -0.25 -0.50 -0.04
Income Tax Expense		 -0.00 0.01 0.00 -1.74 0.01 0.01 -0.00 0.00 0.00 0.00 0.01
Basic Earnings per Share		 ($0.38) ($0.33) ($0.33) ($0.32) ($0.36) ($0.30) ($0.31) ($0.21) ($0.29) ($0.17) ($0.23)
Weighted Average Basic Shares Outstanding		 24.07M 26.58M 32.99M 35.14M 41.12M 43.16M 44.41M 48.60M 49.05M 49.05M 49.05M
Diluted Earnings per Share		 ($0.38) ($0.33) ($0.33) ($0.32) ($0.36) ($0.30) ($0.31) ($0.21) ($0.29) ($0.17) ($0.23)
Weighted Average Diluted Shares Outstanding		 24.07M 26.58M 32.99M 35.14M 41.12M 43.16M 44.41M 48.60M 49.05M 49.05M 49.05M
Weighted Average Basic & Diluted Shares Outstanding		 24.07M 26.58M 32.99M 35.14M 41.12M 43.16M 44.41M 48.60M 49.05M 49.05M 49.05M

Quarterly Income Statements for MediciNova

This table shows MediciNova's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Consolidated Net Income / (Loss)		 -0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Net Income / (Loss) Continuing Operations		 -0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Total Pre-Tax Income 		-0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Total Operating Income		 -1.15 -2.49 -3.14 -3.05 -3.31 -3.18 -3.20 -3.61 -3.38 -2.84
Total Gross Profit		 1.00 - 0.00 0.00 0.00 - 0.00 0.13 0.12 0.19
Total Revenue		 1.00 - 0.00 0.00 0.00 - 0.00 0.13 0.12 0.19
Operating Revenue		 1.00 - 0.00 0.00 0.00 - 0.00 0.13 0.12 0.19
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.15 2.49 3.14 3.05 3.31 3.18 3.20 3.74 3.50 3.02
Selling, General & Admin Expense		 1.35 0.84 1.35 1.40 1.45 1.28 1.36 1.55 1.92 1.76
Research & Development Expense		 0.79 1.65 1.78 1.65 1.86 1.91 1.84 2.19 1.58 1.26
Total Other Income / (Expense), net		 0.42 0.43 0.38 0.42 0.46 0.37 0.34 0.33 0.33 0.25
Interest & Investment Income		 0.44 0.44 0.40 0.44 0.45 0.39 0.34 0.32 0.34 0.25
Other Income / (Expense), net		 -0.01 -0.00 -0.02 -0.02 0.01 -0.02 0.00 0.00 -0.01 -0.00
Basic Earnings per Share		 ($0.01) ($0.04) ($0.06) ($0.05) ($0.06) ($0.06) ($0.06) ($0.07) ($0.06) ($0.05)
Weighted Average Basic Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M
Diluted Earnings per Share		 ($0.01) ($0.04) ($0.06) ($0.05) ($0.06) ($0.06) ($0.06) ($0.07) ($0.06) ($0.05)
Weighted Average Diluted Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M
Weighted Average Basic & Diluted Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M

Annual Cash Flow Statements for MediciNova

This table details how cash moves in and out of MediciNova's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 4.97 10 2.04 3.87 34 1.48 -3.76 11 -53 32 -11
Net Cash From Operating Activities		 0.82 -7.15 -6.55 -6.92 -9.11 -9.12 -11 -9.38 -13 -7.43 -11
Net Cash From Continuing Operating Activities		 0.82 -7.15 -9.42 -8.49 -9.11 -9.12 -11 -9.38 -13 -7.43 -11
Net Income / (Loss) Continuing Operations		 -9.20 -8.85 -11 -11 -15 -13 -14 -10 -14 -8.57 -11
Consolidated Net Income / (Loss)		 -9.20 -8.85 -11 -11 -15 -13 -14 -10 -14 -8.57 -11
Depreciation Expense		 0.04 0.03 0.01 0.03 0.03 0.02 0.02 0.03 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 1.62 2.06 1.13 1.40 6.20 4.11 3.39 1.93 0.81 1.01 1.37
Changes in Operating Assets and Liabilities, net		 8.35 -0.39 0.30 1.25 -0.66 -0.32 -0.38 -1.21 0.33 0.11 -0.98
Net Cash From Investing Activities		 -0.00 -0.00 -0.08 0.00 0.63 -0.01 -0.04 -0.03 -40 40 -0.00
Net Cash From Continuing Investing Activities		 -0.00 -0.00 -0.08 0.00 0.63 -0.01 -0.04 -0.03 -40 40 -0.00
Purchase of Property, Plant & Equipment		 -0.00 -0.00 -0.08 0.00 -0.01 -0.01 -0.04 -0.03 -0.01 -0.02 -0.00
Purchase of Investments		 - - - - - - - 0.00 -60 0.00 0.00
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - - 0.00 20 40 0.00
Net Cash From Financing Activities		 4.16 18 8.67 11 43 11 7.11 21 0.01 0.00 0.00
Net Cash From Continuing Financing Activities		 4.16 18 8.67 11 43 11 7.11 21 0.01 0.00 0.00
Issuance of Common Equity		 4.16 18 8.67 11 43 11 7.31 21 0.01 0.00 0.00
Effect of Exchange Rate Changes		 -0.01 -0.00 0.01 0.00 - - 0.00 0.03 -0.02 0.02 0.00
Cash Income Taxes Paid		 0.01 0.01 0.01 0.01 0.01 0.01 0.00 - 0.00 0.00 0.01

Quarterly Cash Flow Statements for MediciNova

This table details how cash moves in and out of MediciNova's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.37 -0.51 -3.86 -2.80 -2.06 -1.92 -3.79 -2.31 -1.70 -3.48
Net Cash From Operating Activities		 -1.37 -0.50 -3.87 -2.81 -2.03 -1.93 -3.78 -2.31 -1.70 -3.47
Net Cash From Continuing Operating Activities		 -1.37 -0.50 -3.87 -2.81 -2.03 -1.93 -3.78 -2.31 -1.70 -3.47
Net Income / (Loss) Continuing Operations		 -0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Consolidated Net Income / (Loss)		 -0.72 -2.06 -2.75 -2.63 -2.85 -2.81 -2.86 -3.28 -3.05 -2.59
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.27 -0.19 0.26 0.24 0.55 0.31 0.33 0.25 0.20 0.45
Changes in Operating Assets and Liabilities, net		 -0.92 1.74 -1.38 -0.43 0.27 0.57 -1.26 0.72 1.14 -1.34
Net Cash From Investing Activities		 -0.00 0.00 0.00 -0.00 0.00 0.00 0.00 - -0.00 -0.01
Net Cash From Continuing Investing Activities		 -0.00 0.00 0.00 -0.00 0.00 0.00 0.00 - -0.00 -0.01
Purchase of Property, Plant & Equipment		 -0.00 0.00 0.00 -0.00 -0.00 0.00 0.00 - -0.00 -0.01
Sale of Property, Plant & Equipment		 - - 0.00 - 0.00 -0.00 0.00 - - 0.00
Sale and/or Maturity of Investments		 - - 0.00 - - - 0.00 - - 0.00
Net Cash From Financing Activities		 - - 0.00 - - - 0.00 - - 0.00
Net Cash From Continuing Financing Activities		 - - 0.00 - - - 0.00 - - 0.00
Effect of Exchange Rate Changes		 0.01 -0.01 0.01 0.01 -0.03 0.01 -0.00 -0.01 0.01 0.00

Annual Balance Sheets for MediciNova

This table presents MediciNova's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 38 40 43 77 79 75 87 74 66 56 46
Total Current Assets		 23 25 28 63 64 61 72 59 51 41 31
Cash & Equivalents		 22 24 28 62 64 60 71 19 51 40 31
Accounts Receivable		 - - - - - - - - - 0.00 0.00
Prepaid Expenses		 0.65 0.59 0.34 0.44 0.51 0.68 0.58 0.50 0.17 0.71 0.18
Plant, Property, & Equipment, net		 0.02 0.09 0.06 0.05 0.04 0.06 0.06 0.05 0.05 0.03 0.01
Total Noncurrent Assets		 15 15 15 14 15 15 15 15 15 15 15
Goodwill		 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60
Other Noncurrent Operating Assets		 4.91 4.80 4.81 4.81 5.26 5.05 5.74 5.52 5.45 5.18 5.00
Total Liabilities & Shareholders' Equity		 38 40 43 77 79 75 87 74 66 56 46
Total Liabilities		 5.15 5.28 4.78 4.12 4.31 4.09 3.73 3.91 3.89 3.37 4.02
Total Current Liabilities		 1.49 1.63 2.88 2.19 2.23 2.19 2.83 3.19 3.28 2.96 3.80
Accounts Payable		 0.17 0.37 1.52 0.62 0.45 0.62 0.40 0.42 1.00 1.10 0.62
Accrued Expenses		 1.32 1.26 1.36 1.58 1.78 1.39 2.30 2.61 2.06 1.66 2.61
Current Deferred Revenue		 - - - - - - - - - 0.00 0.37
Other Current Liabilities		 - - - - - 0.19 0.13 0.16 0.22 0.19 0.19
Total Noncurrent Liabilities		 3.66 3.65 1.90 1.92 2.08 1.90 0.90 0.73 0.61 0.41 0.22
Noncurrent Deferred & Payable Income Tax Liabilities		 1.96 1.96 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Other Noncurrent Operating Liabilities		 - - - 0.03 0.19 0.00 0.69 0.52 0.41 0.21 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 33 35 39 73 75 71 84 70 62 53 42
Total Preferred & Common Equity		 33 35 39 73 75 71 84 70 62 53 42
Total Common Equity		 33 35 39 73 75 71 84 70 62 53 42
Common Stock		 352 365 380 429 444 454 477 477 478 479 480
Retained Earnings		 -319 -330 -341 -356 -369 -383 -393 -407 -416 -427 -439
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.10 -0.09 -0.09 -0.09 -0.09 -0.10 -0.12 -0.12 -0.14 -0.13

Quarterly Balance Sheets for MediciNova

This table presents MediciNova's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 68 63 60 58 52 50 48 43
Total Current Assets		 53 48 46 43 38 35 33 28
Cash & Equivalents		 52 47 44 42 37 34 33 27
Accounts Receivable		 1.00 - - - - 0.13 0.00 0.25
Prepaid Expenses		 0.49 0.72 1.17 0.98 1.11 0.73 0.36 0.57
Plant, Property, & Equipment, net		 0.05 0.04 0.04 0.03 0.02 0.02 0.01 0.01
Total Noncurrent Assets		 15 15 15 15 15 15 15 15
Goodwill		 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60
Other Noncurrent Operating Assets		 5.49 5.39 5.26 5.22 5.13 5.08 5.04 4.94
Total Liabilities & Shareholders' Equity		 68 63 60 58 52 50 48 43
Total Liabilities		 3.47 3.06 3.00 3.05 2.50 2.97 3.61 3.30
Total Current Liabilities		 2.80 2.51 2.49 2.60 2.13 2.65 3.34 3.10
Accounts Payable		 0.74 0.80 0.67 0.71 0.72 0.57 0.75 0.85
Accrued Expenses		 1.86 1.49 1.64 1.69 1.22 1.89 1.89 1.65
Current Deferred Revenue		 - - - - - 0.00 0.52 0.43
Other Current Liabilities		 0.21 0.22 0.19 0.20 0.19 0.18 0.18 0.17
Total Noncurrent Liabilities		 0.67 0.55 0.50 0.46 0.37 0.32 0.28 0.20
Noncurrent Deferred & Payable Income Tax Liabilities		 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Other Noncurrent Operating Liabilities		 0.46 0.35 0.30 0.26 0.17 0.12 0.07 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 65 60 57 55 50 47 44 39
Total Preferred & Common Equity		 65 60 57 55 50 47 44 39
Total Common Equity		 65 60 57 55 50 47 44 39
Common Stock		 478 478 479 479 480 480 480 481
Retained Earnings		 -414 -418 -421 -424 -430 -433 -436 -441
Accumulated Other Comprehensive Income / (Loss)		 -0.12 -0.13 -0.13 -0.12 -0.13 -0.13 -0.13 -0.13

Annual Metrics And Ratios for MediciNova

This table displays calculated financial ratios and metrics derived from MediciNova's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding		 24,219,317.00 29,956,495.00 34,487,430.00 36,100,733.00 41,881,306.00 43,841,965.00 44,927,560.00 49,043,246.00 49,046,246.00 49,046,246.00 49,046,246.00
DEI Adjusted Shares Outstanding		 24,219,317.00 29,956,495.00 34,487,430.00 36,100,733.00 41,881,306.00 43,841,965.00 44,927,560.00 49,043,246.00 49,046,246.00 49,046,246.00 49,046,246.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.38 -0.30 -0.32 -0.31 -0.35 -0.30 -0.31 -0.21 -0.29 -0.17 -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00%
EBITDA Growth		 -133.40% 3.80% -23.88% -19.33% -19.65% 9.82% -1.01% 27.80% -44.97% 30.12% -22.26%
EBIT Growth		 -128.57% 3.93% -23.67% -19.43% -19.59% 9.82% -0.99% 27.72% -44.77% 30.07% -22.22%
NOPAT Growth		 -129.40% 4.34% -23.34% -19.71% -19.65% 9.98% -1.05% 27.95% -43.20% 32.32% -28.03%
Net Income Growth		 -128.25% 3.81% -22.85% -2.73% -31.46% 11.81% -7.05% 26.85% -38.83% 39.08% -28.91%
EPS Growth		 -100.00% 13.16% 0.00% 3.03% -12.50% 16.67% -3.33% 32.26% -38.10% 41.38% -35.29%
Operating Cash Flow Growth		 107.67% -975.95% 8.47% -5.77% -31.63% -0.12% -18.65% 13.34% -37.63% 42.45% -43.22%
Free Cash Flow Firm Growth		 118.13% -438.80% -12.87% -26.67% -24.73% 13.21% 0.17% 19.83% -20.24% 32.76% -47.03%
Invested Capital Growth		 -46.49% 3.83% -2.30% 2.43% 7.58% 2.85% 1.69% 8.47% -4.02% -3.19% 6.72%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -172.99% -4.15% 10.03% -17.23% 15.88% -14.01% -6.01% 8.13% -9.68% 8.26% -5.90%
EBIT Q/Q Growth		 -170.96% -4.06% 10.02% -17.23% 15.86% -13.98% -6.00% 8.11% -9.65% 8.24% -5.89%
NOPAT Q/Q Growth		 -170.25% -4.17% 10.64% -17.78% 15.75% -14.08% -5.90% 8.18% -8.36% 6.96% -5.79%
Net Income Q/Q Growth		 -170.35% -4.18% 10.58% -1.40% 8.68% -15.91% -7.79% 8.17% -6.98% 9.91% -7.34%
EPS Q/Q Growth		 -280.00% 0.00% 13.16% 0.00% 10.00% -20.00% -6.90% 8.70% -7.41% 15.00% -9.52%
Operating Cash Flow Q/Q Growth		 137.59% -7.26% 6.54% 0.18% -7.02% -9.09% 4.04% -21.97% -2.93% 32.07% -15.56%
Free Cash Flow Firm Q/Q Growth		 173.27% -10.48% 11.14% -30.55% 19.47% -12.82% -3.34% -10.25% -13.75% 34.67% -20.32%
Invested Capital Q/Q Growth		 -6.77% -3.16% -3.42% 4.87% -2.84% -3.28% -5.06% 6.89% 11.13% -13.55% -5.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -253.85% 0.00% -1,038.28% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -253.02% 0.00% -990.03% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -254.50% 0.00% -1,040.31% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -251.00% 0.00% -857.15% 0.00%
Tax Burden Percent		 99.96% 100.08% 100.03% 86.49% 100.04% 100.10% 99.99% 100.03% 100.02% 100.04% 100.05%
Interest Burden Percent		 100.01% 100.01% 99.39% 98.89% 93.98% 91.84% 97.46% 98.60% 94.56% 82.36% 86.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -60.77% 0.00% -59.92% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -56.23% 0.00% -56.92% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 47.69% 0.00% 46.99% 0.00%
Return on Equity (ROE)		 -38.77% -32.30% -32.30% -30.51% -26.26% -17.49% -18.95% -13.08% -18.28% -12.93% -19.24%
Cash Return on Invested Capital (CROIC)		 13.95% -66.51% -74.54% -94.38% -112.07% -92.52% -90.32% -68.89% -81.23% -56.67% -81.94%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.62% 0.00% -14.82% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.45% 0.00% -12.21% 0.00%
Return on Common Equity (ROCE)		 -38.77% -32.30% -32.30% -30.51% -26.26% -17.49% -18.95% -13.08% -18.28% -12.93% -19.24%
Return on Equity Simple (ROE_SIMPLE)		 -41.78% -27.01% -31.47% -28.89% -20.07% -17.28% -19.42% -12.11% -20.03% -13.74% -21.05%
Net Operating Profit after Tax (NOPAT)		 -6.46 -6.18 -7.62 -9.12 -11 -9.82 -9.92 -7.15 -10 -6.93 -8.87
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -177.12% 0.00% -693.02% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -27.76% -15.22% -13.69% -7.66% -8.28% -4.95% -6.35% -4.54% -5.89% -3.00% -4.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -11.11% -16.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 141.56% 0.00% 524.24% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 211.47% 0.00% 565.79% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 353.02% 0.00% 1,090.03% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.20 -8.84 -11 -13 -16 -14 -14 -10 -15 -10 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.16 -8.81 -11 -13 -16 -14 -14 -10 -15 -10 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.35 3.25 6.02 6.04 4.68 3.95 3.31 1.57 1.43 1.18 1.96
Price to Tangible Book Value (P/TBV)		 5.93 4.59 8.34 8.04 5.39 4.53 3.83 1.77 1.66 1.39 2.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32.55 0.00 73.57 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.35 8.34 18.70 20.43 25.93 20.87 15.61 4.90 3.58 1.98 5.16
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.86 0.00 22.57 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 75.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 31.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.42 -0.64 -0.71 -0.73 -0.81 -0.85 -0.85 -0.85 -0.84 -0.83 -0.80
Leverage Ratio		 1.20 1.19 1.16 1.14 1.08 1.06 1.06 1.05 1.05 1.06 1.06
Compound Leverage Factor		 1.20 1.19 1.15 1.12 1.01 0.97 1.03 1.04 0.99 0.87 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -8.20 0.49 11.80 18.04 43.71 34.96 27.85 15.46 7.97 2.93 7.70
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.61 15.25 15.16 9.83 28.63 28.86 27.67 25.42 18.51 15.61 13.88
Quick Ratio		 7.32 14.81 14.80 9.72 28.43 28.63 27.36 25.21 18.35 15.55 13.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.93 -6.55 -7.39 -9.36 -12 -10 -10 -8.11 -9.75 -6.55 -9.64
Operating Cash Flow to CapEx		 23,177.09% -308,291.81% -7,748.56% 0.00% -89,354.13% -80,952.69% -29,667.77% -32,652.11% -257,715.83% -34,889.14% -1,526,967.58%
Free Cash Flow to Firm to Interest Expense		 3,076.13 -12,733.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 1,300.21 -13,915.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 1,294.60 -13,919.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 71.29 0.00 21.96 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.66 10 9.80 10 11 11 11 12 12 11 12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.09 0.00
Increase / (Decrease) in Invested Capital		 -8.39 0.37 -0.23 0.24 0.76 0.31 0.19 0.96 -0.49 -0.38 0.76
Enterprise Value (EV)		 61 84 183 205 280 232 176 60 42 23 63
Market Capitalization		 74 106 208 234 342 295 236 131 101 74 103
Book Value per Share		 $0.91 $1.09 $1.00 $1.07 $1.75 $1.71 $1.59 $1.71 $1.43 $1.27 $1.07
Tangible Book Value per Share		 $0.51 $0.77 $0.72 $0.80 $1.52 $1.49 $1.37 $1.51 $1.24 $1.08 $0.87
Total Capital		 22 33 35 39 73 75 71 84 70 62 53
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -23 -25 -29 -62 -64 -60 -71 -58 -51 -40
Capital Expenditures (CapEx)		 0.00 0.00 0.08 0.00 0.01 0.01 0.04 0.03 0.01 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.13 -0.84 -1.04 -2.54 -1.75 -1.72 -1.51 -2.25 -2.69 -3.10 -2.24
Debt-free Net Working Capital (DFNWC)		 11 21 23 25 61 62 59 69 56 48 38
Net Working Capital (NWC)		 11 21 23 25 61 62 59 69 56 48 38
Net Nonoperating Expense (NNE)		 2.74 2.67 3.25 2.04 3.76 3.12 3.93 2.98 3.83 1.64 2.18
Net Nonoperating Obligations (NNO)		 -12 -23 -25 -29 -62 -64 -60 -71 -58 -51 -40
Total Depreciation and Amortization (D&A)		 0.04 0.03 0.01 0.03 0.03 0.02 0.02 0.03 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -55.85% 0.00% -310.42% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,713.34% 0.00% 4,789.53% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,713.34% 0.00% 4,789.53% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.38) ($0.33) ($0.33) ($0.32) ($0.36) ($0.30) ($0.31) ($0.21) $0.00 ($0.17) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding		 24.62M 30.00M 34.53M 40.93M 42.17M 43.96M 48.68M 49.04M 0.00 49.05M 49.05M
Adjusted Diluted Earnings per Share		 ($0.38) ($0.33) ($0.33) ($0.32) ($0.36) ($0.30) ($0.31) ($0.21) $0.00 ($0.17) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding		 24.62M 30.00M 34.53M 40.93M 42.17M 43.96M 48.68M 49.04M 0.00 49.05M 49.05M
Adjusted Basic & Diluted Earnings per Share		 ($0.38) ($0.33) ($0.33) ($0.32) ($0.36) ($0.30) ($0.31) ($0.21) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 24.07M 26.58M 32.99M 35.14M 41.12M 43.16M 44.41M 48.60M 0.00 49.05M 49.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.46 -6.18 -7.62 -9.12 -11 -9.82 -9.92 -7.15 -10 -6.93 -8.87
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -177.12% 0.00% -693.02% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -250.94% 0.00% -856.85% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -14,647.51 -17,193.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -10,280.43 -12,014.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -14,653.12 -17,197.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -10,286.04 -12,019.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -2.23% -1.47% -1.17% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MediciNova

This table displays calculated financial ratios and metrics derived from MediciNova's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00
DEI Adjusted Shares Outstanding		 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00 49,046,246.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.01 -0.04 -0.06 -0.05 -0.06 -0.06 -0.06 -0.07 -0.06 -0.05
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 70.39% 27.32% 8.06% 7.84% -185.18% -28.44% -1.54% -17.75% -2.76% 11.27%
EBIT Growth		 70.28% 27.25% 8.01% 7.81% -184.23% -28.36% -1.53% -17.71% -2.76% 11.28%
NOPAT Growth		 70.57% 22.94% -5.83% 7.68% -188.53% -27.85% -2.12% -18.40% -2.17% 11.45%
Net Income Growth		 80.20% 31.40% 5.59% 8.48% -294.43% -36.69% -3.98% -24.85% -6.95% 9.70%
EPS Growth		 85.71% 42.86% 0.00% 16.67% -500.00% -50.00% 0.00% -40.00% 0.00% 16.67%
Operating Cash Flow Growth		 49.58% 87.55% -21.74% -17.96% -48.16% -287.07% 2.19% 17.95% 16.18% 8.28%
Free Cash Flow Firm Growth		 -83.33% 22.73% -51.75% -267.72% 42.75% -118.86% -12.44% 86.48% 49.27% 75.80%
Invested Capital Growth		 24.44% -3.19% 3.19% 0.00% -2.86% 6.72% 5.26% -3.60% -10.82% -9.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.38% 0.00%
EBITDA Q/Q Growth		 65.18% -115.25% -26.53% 2.81% -7.74% 3.06% -0.03% -12.71% 5.97% 0.00%
EBIT Q/Q Growth		 65.06% -114.66% -26.47% 2.81% -7.72% 3.06% -0.03% -12.68% 5.96% 0.00%
NOPAT Q/Q Growth		 65.25% -117.12% -25.94% 2.85% -8.62% 3.79% -0.59% -12.63% 6.27% 0.00%
Net Income Q/Q Growth		 74.82% -184.76% -33.77% 4.59% -8.52% 1.32% -1.76% -14.56% 7.03% 0.00%
EPS Q/Q Growth		 83.33% -300.00% -50.00% 16.67% -20.00% 0.00% 0.00% -16.67% 14.29% 0.00%
Operating Cash Flow Q/Q Growth		 42.44% 63.61% -675.11% 27.33% 27.71% 4.94% -95.87% 39.04% 26.15% 0.00%
Free Cash Flow Firm Q/Q Growth		 -137.38% 59.63% -89.16% -487.51% 87.24% -54.35% 2.82% 29.36% 52.12% 0.00%
Invested Capital Q/Q Growth		 0.00% -13.55% 11.54% 2.96% -2.16% -5.01% 10.01% -5.70% -9.49% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -115.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,675.41% -2,745.66% -1,516.15%
Operating Margin		 -114.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,679.88% -2,741.67% -1,516.60%
EBIT Margin		 -116.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,679.17% -2,749.96% -1,518.43%
Profit (Net Income) Margin		 -72.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,437.75% -2,473.56% -1,383.14%
Tax Burden Percent		 100.00% 100.15% 100.00% 100.00% 100.00% 100.20% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 62.28% 82.50% 87.39% 85.79% 86.43% 87.81% 89.50% 90.99% 89.95% 91.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -6.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.68% -40.93% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -6.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.75% -39.10% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 5.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.38% 29.55% 0.00%
Return on Equity (ROE)		 -1.05% 0.00% 0.00% 0.00% -17.19% -19.24% -20.33% -6.29% -11.38% 0.00%
Cash Return on Invested Capital (CROIC)		 -84.54% -56.67% -59.57% -305.20% -61.74% -81.94% -73.60% -68.90% -65.98% 10.07%
Operating Return on Assets (OROA)		 -1.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.54% -13.42% 0.00%
Return on Assets (ROA)		 -0.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.95% -12.07% 0.00%
Return on Common Equity (ROCE)		 -1.05% 0.00% 0.00% 0.00% -17.19% -19.24% -20.33% -6.29% -11.38% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -14.71% 0.00% -14.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.80 -1.74 -2.20 -2.13 -2.32 -2.23 -2.24 -2.52 -2.37 -1.99
NOPAT Margin		 -80.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,875.92% -1,919.17% -1,061.62%
Net Nonoperating Expense Percent (NNEP)		 0.14% -0.58% -1.12% -2.24% -1.14% -1.28% -1.49% -1.92% -1.83% -1.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.79% -3.67% -3.71% -4.21% -4.24% -4.49% -5.39% -5.38% -5.04%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 135.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,153.83% 1,558.03% 941.40%
R&D to Revenue		 79.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,626.05% 1,283.64% 675.20%
Operating Expenses to Revenue		 214.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,779.88% 2,841.67% 1,616.60%
Earnings before Interest and Taxes (EBIT)		 -1.16 -2.49 -3.15 -3.06 -3.30 -3.20 -3.20 -3.61 -3.39 -2.84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.16 -2.49 -3.15 -3.06 -3.29 -3.19 -3.20 -3.60 -3.39 -2.83
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.59 1.18 1.19 1.23 1.87 1.96 1.43 1.37 1.42 1.71
Price to Tangible Book Value (P/TBV)		 1.86 1.39 1.42 1.48 2.27 2.40 1.78 1.72 1.81 2.25
Price to Revenue (P/Rev)		 102.51 73.57 71.12 70.63 0.00 0.00 0.00 477.35 241.51 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.87 1.98 1.89 2.01 4.75 5.16 2.62 2.38 2.61 3.30
Enterprise Value to Revenue (EV/Rev)		 51.00 22.57 23.98 26.29 0.00 0.00 0.00 222.82 115.25 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31.11
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.83 -0.83 -0.80 -0.77 -0.78 -0.80 -0.76 -0.75 -0.76 -0.72
Leverage Ratio		 1.06 1.06 1.05 1.05 1.05 1.06 1.05 1.06 1.07 1.06
Compound Leverage Factor		 0.66 0.87 0.92 0.90 0.91 0.93 0.94 0.96 0.96 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.08 3.32 5.33 5.08 10.68 8.26 6.32 1.38 -1.97 -1.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 18.92 15.61 19.07 18.24 16.66 13.88 17.66 13.26 9.86 9.09
Quick Ratio		 18.74 15.55 18.78 17.78 16.28 13.64 17.14 12.99 9.76 8.91
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.39 -1.37 -2.59 -15 -1.94 -2.99 -2.91 -2.05 -0.98 -0.70
Operating Cash Flow to CapEx		 -49,983.56% 0.00% 0.00% -315,480.36% 0.00% 0.00% 0.00% 0.00% -58,751.19% -32,057.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 20.59 21.96 21.06 27.92 0.00 0.00 0.00 5.26 11.79 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 13 11 13 13 13 12 13 13 11 12
Invested Capital Turnover		 0.08 0.09 0.08 0.15 0.00 0.00 0.00 0.01 0.02 0.00
Increase / (Decrease) in Invested Capital		 2.59 -0.38 0.39 13 -0.38 0.76 0.67 -0.47 -1.38 -1.28
Enterprise Value (EV)		 51 23 24 26 61 63 35 30 30 40
Market Capitalization		 103 74 71 71 103 103 72 64 62 67
Book Value per Share		 $1.32 $1.27 $1.22 $1.17 $1.12 $1.07 $1.02 $0.96 $0.90 $0.80
Tangible Book Value per Share		 $1.12 $1.08 $1.02 $0.97 $0.93 $0.87 $0.82 $0.76 $0.70 $0.61
Total Capital		 65 62 60 57 55 53 50 47 44 39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -52 -51 -47 -44 -42 -40 -37 -34 -33 -27
Capital Expenditures (CapEx)		 0.00 -0.00 0.00 0.00 -0.00 -0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.31 -3.10 -1.79 -1.33 -1.61 -2.24 -1.03 -1.78 -2.98 -2.28
Debt-free Net Working Capital (DFNWC)		 50 48 45 43 41 38 36 32 30 25
Net Working Capital (NWC)		 50 48 45 43 41 38 36 32 30 25
Net Nonoperating Expense (NNE)		 -0.08 0.32 0.56 0.50 0.54 0.59 0.62 0.76 0.68 0.60
Net Nonoperating Obligations (NNO)		 -52 -51 -47 -44 -42 -40 -37 -34 -33 -27
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -131.29% -310.42% -178.57% -132.66% 0.00% 0.00% 0.00% -1,325.40% -1,154.45% 0.00%
Debt-free Net Working Capital to Revenue		 5,019.45% 4,789.53% 4,535.31% 4,301.12% 0.00% 0.00% 0.00% 24,127.71% 11,470.73% 0.00%
Net Working Capital to Revenue		 5,019.45% 4,789.53% 4,535.31% 4,301.12% 0.00% 0.00% 0.00% 24,127.71% 11,470.73% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) ($0.04) ($0.06) ($0.05) ($0.06) ($0.06) ($0.06) ($0.07) ($0.06) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M
Adjusted Diluted Earnings per Share		 ($0.01) ($0.04) ($0.06) ($0.05) ($0.06) ($0.06) ($0.06) ($0.07) ($0.06) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.05M 49.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.80 -1.74 -2.20 -2.13 -2.32 -2.23 -2.24 -2.52 -2.37 -1.99
Normalized NOPAT Margin		 -80.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,875.92% -1,919.17% -1,061.62%
Pre Tax Income Margin		 -72.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,437.75% -2,473.56% -1,383.14%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

MediciNova (NASDAQ: MNOV) remains a development-stage biotech with very limited revenue and persistent quarterly losses. The latest quarter, Q1 2026, shows a continued cash burn, but the balance sheet still carries a meaningful cash cushion that gives the company time to fund operations.

Key takeaways from the last several quarters:

  • MNOV ended Q1 2026 with $27.3 million in cash and equivalents, which is down from $32.6 million at Q3 2025 but still provides a reasonable near-term liquidity buffer.
  • The company had no financing cash inflow in Q1 2026, suggesting it did not need to raise capital in the quarter.
  • Operating revenue is at least present in recent quarters, including $187,000 in Q1 2026, $123,000 in Q3 2025, and $135,000 in Q2 2025, indicating some recurring collaboration or contract activity.
  • Revenue has shown a sequential improvement from Q3 2025 to Q1 2026, rising from $123,000 to $187,000.
  • Total liabilities remain relatively low at $3.3 million in Q1 2026 versus $42.7 million in assets, leaving shareholders’ equity at $39.4 million.
  • Interest and investment income continues to help offset expenses, contributing $253,000 in Q1 2026 and $341,000 in Q3 2025.
  • The company’s quarterly share count has remained flat at roughly 49.2 million shares, with no meaningful dilution visible in the periods provided.
  • Research and development spending remains substantial, reflecting continued pipeline investment, though the mix of spending has shifted quarter to quarter.
  • MNOV is still deeply unprofitable, posting a Q1 2026 net loss of $2.6 million and a Q3 2025 loss of $3.1 million.
  • Operating cash flow was negative $3.5 million in Q1 2026, after negative $1.7 million in Q3 2025 and negative $2.3 million in Q2 2025, showing ongoing cash burn from operations.

Trend overview: Over the last four years of quarterly data, MediciNova has stayed in loss-making territory, with operating expenses consistently running well above revenue. Revenue is still very small relative to spending, so the business model remains heavily dependent on future clinical, licensing, or partnership success. The balance sheet, however, is still intact and cash levels remain large enough for a small biotech, which reduces immediate financing risk.

Bottom line: MNOV’s financials are better described as stable but speculative rather than fundamentally strong. The company has enough cash for now, but investors should watch for continued losses, cash burn, and whether revenue can meaningfully scale before the cash balance declines further.

07/17/26 02:59 AM ETAI Generated. May Contain Errors.

MediciNova Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MediciNova's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

MediciNova's net income were at -$11.05 million at the end of 2024, a 28.9% increase from 2023, and a 20.2% increase since 2014. See MediciNova's forecast for analyst expectations on what's next for the company.

MediciNova's total operating income in 2024 was -$12.68 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $12.68 million

Over the last 10 years, MediciNova's total revenue changed from $0.00 in 2014 to $0.00 in 2024, a change of 0.0%.

MediciNova's total liabilities were at $4.02 million at the end of 2025, a 19.1% increase from 2024, and a 22.1% decrease since 2015.

In the past 10 years, MediciNova's cash and equivalents has ranged from $18.51 million in 2022 to $71.43 million in 2021, and is currently $30.81 million as of their latest financial filing in 2025.

Over the last 10 years, MediciNova's book value per share changed from 0.91 in 2014 to 1.07 in 2024, a change of 17.8%.


Related Companies

Financial statements for NASDAQ:MNOV last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel